Getting your player ready...
WASHINGTON — The Food and Drug Administration said Tuesday it was halting importation of 28 drugs made by the giant Indian generic drugmaker, Ranbaxy Laboratories, because of manufacturing deficiencies at two of the company’s plants.
Douglas Throckmorton, a physician with FDA’s Center for Drug Evaluation, said there was “no evidence of harm to consumers” of drugs made at the Dewas and Paonta Sahib plants, both in India.
He characterized the import ban as “a preventive action.”
FDA officials said numerous tests of the drugs have found they are not contaminated, subpotent or unsafe and urged patients taking the drugs not to stop. It said the nature of the violations relates to the manufacturing process.
